5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 5.85▼ | 5.84▼ | 5.81▲ | 5.81▲ | 5.93▼ |
MA10 | 5.81▲ | 5.79▲ | 5.80▲ | 5.86▼ | 5.80▲ |
MA20 | 5.79▲ | 5.85▼ | 5.89▼ | 5.96▼ | 6.11▼ |
MA50 | 5.90▼ | 5.90▼ | 5.94▼ | 5.75▲ | 5.23▲ |
MA100 | 5.93▼ | 5.97▼ | 5.91▼ | 6.08▼ | 9.55▼ |
MA200 | 5.88▼ | 5.90▼ | 6.02▼ | 5.43▲ | 32.96▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.014▲ | 0.006▲ | -0.004▼ | -0.032▼ | -0.054▼ |
RSI | 48.750▼ | 46.725▼ | 46.319▼ | 47.897▼ | 49.231▼ |
STOCH | 70.008 | 68.140 | 44.363 | 31.986 | 69.250 |
WILL %R | -53.030 | -50.000 | -50.000 | -69.834 | -44.366 |
CCI | 108.791▲ | 56.795 | 30.819 | -76.983 | -17.375 |
Wednesday, May 14, 2025 06:05 AM
CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3 ...
|
Monday, January 20, 2025 04:00 PM
Therefore, it is recommended to visit the company's website for up to date information. Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any ...
|
Monday, October 21, 2024 05:00 PM
Fintel reports that on October 24, 2024, Leerink Partners initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a Outperform recommendation. As of October 22, 2024, the average one-year ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 5.77 | 5.99 | 5.66 | 5.815 | 35,434 |
13/06/25 | 5.92 | 5.9711 | 5.6267 | 5.70 | 10,786 |
12/06/25 | 5.80 | 6.2154 | 5.80 | 5.85 | 6,823 |
11/06/25 | 5.75 | 5.8899 | 5.65 | 5.745 | 10,405 |
10/06/25 | 5.91 | 5.98 | 5.86 | 5.93 | 13,113 |
09/06/25 | 6.14 | 6.14 | 5.835 | 5.86 | 12,907 |
06/06/25 | 5.90 | 6.06 | 5.82 | 6.06 | 16,101 |
05/06/25 | 5.76 | 5.935 | 5.62 | 5.88 | 10,824 |
04/06/25 | 6.00 | 6.0535 | 5.601 | 5.86 | 59,929 |
03/06/25 | 6.10 | 6.10 | 5.8864 | 5.8864 | 18,581 |
|
|
||||
|
|
||||
|
|